RhythmAnalytics vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

RhythmAnalytics

by Biofourmis Singapore Pte.

iPredict Eye Screening

by iHealthScreen

AI Verdict

While both tools leverage AI and hold FDA clearance for clinical decision support, RhythmAnalytics focuses specifically on the automated interpretation of cardiac arrhythmias from ECG data. iPredict Eye Screening, conversely, specializes in AI-powered screening for ophthalmic conditions like AMD, DR, and Glaucoma, with an added component for systemic disease risk prediction. Therefore, their comparability is adjacent, as they both offer AI-driven diagnostic assistance but in distinct medical specialties.

Choose RhythmAnalytics if…

Choose RhythmAnalytics if your primary need is automated, AI-powered interpretation of single-lead ECG data for cardiac arrhythmias. This tool is ideal for healthcare professionals and integrators seeking clinical decision support for over 15 types of cardiac arrhythmias, including AFib and ventricular arrhythmias, particularly in settings utilizing ambulatory ECG monitoring or wearable sensors.

View RhythmAnalytics →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if your focus is on comprehensive AI-powered screening for retinal diseases like age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, especially in primary care settings. This tool also offers risk prediction for systemic diseases such as stroke and heart attack, and integrates with EHR and telemedicine services for efficient, rapid screening and reporting.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	RhythmAnalytics	iPredict Eye Screening
Pricing	Contact vendor	Contact for pricing
Deployment	Cloud-based API	Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iPredict Eye Screening

iPredict Eye Screening emphasizes ease of use with features like no patient preparation, a non-invasive and easy-to-operate advanced touchscreen interface, and fast results (test completed in less than 5 minutes, report in under 60 seconds). RhythmAnalytics, while cloud-based and offering API integration, does not explicitly detail its user interface or ease of operation for healthcare professionals in the provided information.

Clinical Value

iPredict Eye Screening

iPredict Eye Screening offers a broader clinical value by screening for three significant eye diseases (AMD, DR, Glaucoma) and providing risk prediction for systemic diseases like stroke and heart attack. RhythmAnalytics focuses solely on the detection and interpretation of cardiac arrhythmias.

Pricing & Value

iPredict Eye Screening

iPredict Eye Screening provides some transparency regarding its pricing model, estimating $10-$20 per patient screening, which is 20%-40% of Medicare/commercial payor reimbursement. RhythmAnalytics only states 'contact vendor' for pricing, offering no initial insight into cost. This transparency from iPredict allows for a better initial assessment of value.

Enterprise Readiness

RhythmAnalytics

RhythmAnalytics is designed as a cloud-based API for integration, compatible with various FDA-cleared ECG devices, and is part of Biofourmis' broader Biovitalsu2122 platform, which is used in partnerships with leading hospitals like Mayo Clinic and Brigham and Women's Hospital, and with global pharmaceutical companies. This suggests a robust infrastructure and established enterprise partnerships. While iPredict integrates with EHR and telemedicine, its enterprise adoption details are less extensively described.

Innovation

Tie

Both tools demonstrate innovation in their respective fields. RhythmAnalytics utilizes advanced deep learning for automated, highly accurate interpretation of cardiac arrhythmias from single-lead ECG data. iPredict Eye Screening innovates by offering AI-powered screening for multiple retinal diseases and risk prediction for systemic conditions, making it accessible in primary care settings.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details about the level of customer support, available documentation, or training resources for either RhythmAnalytics or iPredict Eye Screening. Therefore, it is not possible to pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	RhythmAnalytics	iPredict Eye Screening
Name	RhythmAnalytics	iPredict Eye Screening
Company	Biofourmis Singapore Pte.	iHealthScreen
Description	FDA-cleared, AI-powered cloud-based software that provides automated interpretation of cardiac arrhythmias from single-lead ECG data, offering clinical decision support for healthcare professionals and integrators.	FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services.
Key Features	AI-based automated interpretation of cardiac arrhythmias; Detection of over 15 types of cardiac arrhythmias (including AFib, ventricular arrhythmias, ectopic beats); Beat-by-beat morphology computation; ECG signal processing and analysis; QRS and Ventricular Ectopic Beat detection; QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis; Cloud-based API for integration; Compatibility with FDA-cleared ECG devices (Holter, event recorders, wearable sensors).	AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Electronic Health Record (EHR) Solutions; AI-Based Telemedicine Service; Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector; Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients; Fast results: test completed in less than 5 minutes, report in under 60 seconds; High accuracy: approximately 95% on average (AMD sensitivity 86.86%, specificity 94.13%); Easy to operate, non-invasive, with an advanced touchscreen interface.
Specialties	Cardiology, Emergency Medicine, Internal Medicine	Family Medicine, Internal Medicine, Ophthalmology

Videos

Demos, reviews, and walkthroughs featuring RhythmAnalytics and iPredict Eye Screening.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply do these tools integrate with existing EHR systems and clinical workflows?

RhythmAnalytics offers a cloud-based API for integration into existing cardiac monitoring solutions or directly into medical devices and wearable sensors, aiming to improve accuracy and scalability of ECG analysis. iPredict Eye Screening provides EHR solutions and integrates with telemedicine services, with reports available in under 60 seconds after a less than 5-minute test.

What are the reported accuracy and sensitivity for each tool in detecting their respective conditions?

RhythmAnalytics demonstrated a sensitivity of 90.8% and specificity of 98.2% for detecting cardiac arrhythmias, outperforming other deep learning systems and a panel of cardiologists. iPredict Eye Screening has shown high accuracy for its screenings: for Diabetic Retinopathy (DR), up to 98.48% accuracy with 97.32% sensitivity and 98.75% specificity; for Age-related Macular Degeneration (AMD), up to 99.2% accuracy with 98.9% sensitivity and 99.5% specificity; and for glaucoma suspect, 89.67% accuracy with 83.33% sensitivity and 93.89% specificity.

What is the typical learning curve for physicians and their staff to effectively use each tool?

iPredict Eye Screening is designed to be easy to operate with a non-invasive, advanced touchscreen interface, and minimum training needed to operate the models is less than 1 hour. RhythmAnalytics is offered as clinical decision support and is intended to be used in conjunction with a physician's knowledge, suggesting it augments existing expertise rather than requiring extensive new training for interpretation.

What kind of customer support and resources are available for implementation and ongoing use?

While specific details on customer support quality are not provided for either tool, Biofourmis, the company behind RhythmAnalytics, works with leading hospitals like Mayo Clinic and Brigham and Women's Hospital, suggesting established support for their integrations. iHealthScreen emphasizes its AI-based telemedicine service and online health risk prediction system, implying support for these integrated features.

Are there audit-trail features to track AI interpretations and physician overrides for clinical and administrative purposes?

RhythmAnalytics provides ECG signal processing and analysis, QRS and Ventricular Ectopic Beat detection, QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis, which would inherently generate data for an audit trail. iPredict Eye Screening delivers fully automated reports with screening results and recommendations, and if referable disease is detected, it recommends an ophthalmologist visit, implying a traceable record of its output.

What are the considerations for rolling out these tools across multiple clinical sites or a large healthcare system?

RhythmAnalytics is cloud-based and offered as a SaaS API, which suggests scalability and easier deployment across multiple sites by integrating into existing cardiac monitoring solutions. iPredict Eye Screening is also cloud-based and accessible in various settings, including primary care, clinics, and hospitals, and its telemedicine features are designed for large-scale screening, indicating suitability for multi-site rollouts.